Statements (58)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:healthcare_organization
|
gptkbp:bfsLayer |
5
|
gptkbp:bfsParent |
gptkb:Rubella_vaccine
|
gptkbp:caused_by |
gptkb:rubella_virus
|
gptkbp:clinical_trial |
mild illness in children
more severe in adults |
gptkbp:common_name |
gptkb:German_measles
|
gptkbp:complications |
gptkb:congenital_rubella_syndrome
|
gptkbp:contraindication |
pregnant women
immunocompromised individuals |
gptkbp:current_use |
gptkb:psychologist
deafness cataracts cardiac defects thrombocytopenic purpura |
gptkbp:duration |
lifetime after infection
|
gptkbp:genetic_diversity |
single serotype
|
gptkbp:genus |
gptkb:Rubivirus
|
gptkbp:geographical_feature |
worldwide
|
gptkbp:historical_event |
first described in 1752
|
https://www.w3.org/2000/01/rdf-schema#label |
rubella
|
gptkbp:hunting_technique |
subcutaneous injection
|
gptkbp:incubation_period |
2 to 3 weeks
|
gptkbp:is_protected_by |
vaccination
|
gptkbp:is_recognized_by |
gptkb:hospital
|
gptkbp:is_tested_for |
PCR testing
Ig M antibody detection |
gptkbp:is_vulnerable_to |
gptkb:MMR_vaccine
rash refrigerated live attenuated vaccine mild fever rare allergic reactions 95% or higher reduced incidence of disease arthralgia administered at 12-15 months booster at 4-6 years decreased congenital rubella syndrome cases introduced in 1969 routine childhood vaccination |
gptkbp:nutritional_value |
gptkb:Togaviridae
|
gptkbp:public_awareness |
immunization programs
important for vaccination |
gptkbp:risk_factor |
pregnant women
|
gptkbp:scientific_classification |
vaccine-preventable disease
|
gptkbp:scientific_goals |
gptkb:2020_target_by_WHO
|
gptkbp:screenings |
before pregnancy
|
gptkbp:social_responsibility |
vaccination campaigns
serological testing common in unvaccinated populations declined due to vaccination |
gptkbp:symptoms |
fever
rash lymphadenopathy |
gptkbp:transmission |
airborne droplets
from mother to fetus |
gptkbp:treatment |
supportive care
|